More Than Just Words
More Than Just Words is a multiyear initiative in the US to drive toward health equity in breast cancer where there is an unmet need.
Disease Education
Reimagining Medicine for Patients With Breast & Women's Cancer
The PI3K Pathway in Cancer
The phosphoinositol 3 kinase (PI3K) pathway has been demonstrated to regulate many cellular processes, and when hyperactivated, to promote cancer. Learn more about the role of PI3K signaling in promoting the survival and proliferation of tumors.
Reimagining Medicine for Patients With Breast & Women's Cancer
Intrinsic Subtypes in HR+/HER2-
Learn more about the prognostic and predictive value of intrinsic subtypes in HR+/HER2- advanced breast cancer and the capacity of these subtypes to subtype switch.
Alpelisib Mechanism of Action in Breast Cancer
Learn more about the investigation of alpelisib and the role of PI3K pathway hyperactivation in HR+/HER2- aBC, HER2+ aBC, and TNBC.
Alpelisib Mechanism of Action in Ovarian Cancer
In ovarian cancer, preclinical and early clinical data suggest that restoration of homologous recombination DNA repair in the tumor is a possible mechanism for resistance to therapy. Learn more about the investigation of alpelisib and the potential role of the PI3K pathway in treatment-resistant ovarian cancer.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data.
aBC = advanced breast cancer; HER2- = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; HR+ = hormone receptor positive; PI3K = phosphoinositol 3 kinase; TNBC = triple-negative breast cancer.
Explore Clinical Trials
Explore Clinical Trials
Adjuvant HER2+
EPIK-B2
Trastuzumab Plus Pertuzumab ± Alpelisib as Maintenance Therapy in PIK3CA-Mutated HER2+ Advanced Breast Cancer
Advanced TNBC
EPIK-B3
Alpelisib Plus Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
HR+/HER2- ABC
EPIK-B5
Alpelesib + Fulvestrant in Patients with HR+, HER2- Advanced Breast Cancer After Treatment with a CDK4/6 Inhibitor and an Aromatase Inhibitor
HGSOC
EPIK-O
Alpelisib Plus Olaparib in Platinum-Resistant or Refractory, Germline BRCA Mutation-Negative, High-Grade Serous Ovarian Cancer
HER2-enriched
HARMONIA
Ribociclib vs Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
